Charité - Universitätsmedizin Berlin

Hospital


Location: Berlin, Germany (DE) DE

ISNI: 0000000122184662

ROR: https://ror.org/001w7jn25

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

NOVEL MUTATIONS AND FINDINGS IN A COHORT OF MCLEOD NEUROACANTHOCYTOSIS, AN X-LINKED HD PHENOCOPY (2021) Peikert K, Schlotter-Weigel B, Montagnese F, Reilich P, Saft C, Marxreiter F, Kohl Z, et al. Conference contribution Response to treatment of uncommon EGFR mutations - a retrospective analysis from the German National Network Genomic Medicine Lung Cancer (nNGM) (2021) Janning M, Sueptitz J, Forstreuter A, Albers-Leischner C, Tufman A, Velthaus-Rusik JL, Reck M, et al. Conference contribution Health-related quality of life (HRQoL) in CML-patients at diagnosis compared to general population (2021) Lorch M, Pfirrmann M, Fabisch C, Oberle L, Kohn D, Kohlbrenner K, Bruemmendorf TH, et al. Conference contribution Patient-reported treatment satisfaction with Rivaroxaban in cancer patients with acute venous thromboembolism - Results from the CONKO-011 trial (2021) Sinn M, Juehling A, Hellmann M, Omar M, Suedhoff T, Stahl M, Krziwanie A, et al. Conference contribution ELDORANDO - Pembrolizumab compared with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115) (2021) Klinghammer K, Graeven U, Ivanyi P, Dietz A, Hahn D, Hackenberg S, Kasper S, et al. Conference contribution Knowledge transfer to enhance the performance of deep learning models for automated classification of B-cell neoplasms (2021) Mallesh N, Zhao M, Meintker L, Hoellein A, Elsner F, Lueling H, Haferlach T, et al. Conference contribution A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP) (2021) Binder M, Meyer O, Rummel M, Nimmerjahn F, Tesanovic T, Sauer T, Matzdorff A Conference contribution Long-term Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes - Interim Analysis of the RELIANCE Registry (2021) Kuemmerle-Deschner J, Henes J, Kortus-Goetze B, Kallinich T, Oommen PT, Rech J, Weller-Heinemann F, et al. Conference contribution Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients (2021) Rech J, Hueber A, Ostergaard M, Tascilar K, Hagen M, Mendez LV, Kleyer A, et al. Conference contribution Influence of Canakinumab Dosing on Long-term Efficacy and Safety in Patients with Cryopyrin-associated Periodic Syndromes (CAPS)-30-months Interim Analysis of the RELIANCE Registry (2021) Kuemmerle-Deschner J, Kortus-Goetze B, Oommen PT, Janda A, Rech J, Kallinich T, Weller-Heinemann F, et al. Conference contribution